

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT

A022104/Janus Trial
(Triplet vs. double chemo)

Coord: A. Ballard
PI: Dr. Zell
Accrual: 7/15

CCTG-CO32
(NEO-RT trial)
(opened 4/29/24)

Coord: P. Yang
PI: Dr. Zell
Accrual: 3/5

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)

(opened 9/14/22)

Coord: A. Ballard
PI: Dr. Zell
Accrual: 5/10

INTRA-OPERATIVE

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

Coord: M. Bauk
PI: Dr. Dayyani
Accrual: 8/11

**1L METASTATIC****A022101**

(at least 4 months of chemo
once metastatic disease is
confirmed)

(opened 12/13/23)

Coord: A. Ballard

PI: Dr. Eng
Accrual: 0/2

2L METASTATIC**ETCTN 10670**

(Abemaciclib + 5-Fluorouracil)

(opened 4/8/25)

Coord: My Nguyen

PI: Dr. Dayyani
Accrual: 2/8

3L METASTATIC**UCI 21-39**

(Pembro + TATE)

Coord: LM Aguilar

PI: Dr. Abi-Jaoudeh
Accrual: 27/30

UCI 24-93

(Fruquintinib)

(opened 5/28/25)

Coord: M Bauk

PI: Dr. Dayyani
Accrual: 0/7

Newly Diagnosed

Advanced/Metastatic

Neoadjuvant

UCI 21-191
(SOC therapy with ctDNA testing)

Coord: A. Ballard
PI: Dr. Dayyani
Accrual: 0/20
Pending activation

UCI 23-184
Pafolacianine for Imaging of Peritoneal Carcinomatosis
(opened 11/13/24)

Coord: LM Aguilar
PI: Dr. Senthil
Accrual: 5/10

ESCC

UCI 24-77
(I-DXd)

Coord: TBD
PI: Dr. Dayyani
Pending activation

Newly Diagnosed Metastatic

UCI 20-87
(IV Paclitaxel + IV 5- FU + IV leucovorin + IP paclitaxel)

Coord: LM Aguilar
PI: Dr. Senthil
Accrual: 29/40

A022102
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 8/14

UCI 21-10
(FOLFOX + nivo + Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 20/27

Recurrent

UCI 23-78
(EGFR and MET-directed antibody)
(opened 3/1/24)

Coord: M. Bauk
PI: Dr. Dayyani
Accrual: 1/3

UCI 16-94
(Tirapazamine, Nivolumab)

Coord: M Duron
PI: Dr. Abi-Jaoudeh
Accrual: 32/40

UCI 23-109
(Disitamab Vedotin + Tucatinib)
(opened 4/25/24)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 2/10

UCI 22-51
(ASP2138)

Coord: N. Ferrand/
P. Yang
PI: Dr. Dayyani
Accrual: 22/25

UCI 23-200
(AZD0901)
(opened 7/24/24)

Coord: M Duron
PI: Dr. Dayyani
Accrual: 4/10

UCI 24-49
(opened 10/22/24)
(Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 0/10

UCI 23-173
(ICI in ARID1a Mu)
Coord: TBD
PI: Dr. Dayyani
Pending activation

HER-2

ETCTN-10358/DASH
(DS8201a + AZD6738)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 5/8

ETCTN-10495
(DS8201a + Neratinib)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 2/7

UCI 24-49
(opened 10/22/24)
(Beamion BCGC-1:
Oral Zongertinib +
Trastuzumab Deruxtecan)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 0/10

KRAS

UCI 24-65
(FMC-376 in KRASG12C)
(opened 11/4/24)

Coord: P. Yang

PI: Dr. Dayyani
Accrual: 1/5

Open to Accrual

EGFR

Low Accruing Pending Activation/Suspended

CLDN18.2

UCI 22-51
(ASP2138)


Coord: N. Ferrand/
P. Yang
PI: Dr. Dayyani

Accrual: 22/25

UCI 23-200
(AZD0901)
(opened 7/24/24)

Coord: J.Koff
PI: Dr. Dayyani

Accrual: 4/10





UCI 03-03
(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

UCI 23-29
(Electroacupuncture in symptom management after CRS/HIPEC)

(opened 8/8/24)
PI: Dr. Eng
Accrual: 3/15

UCI 22-55
(ID GenomeSig for HomoRecomboDeficiency inPC &Mismatch RepairDeficiency in Microsatellite Instable CC)

PI: Dr. Pannunzio/Dr. Valerin
Pending activation